WW International (NASDAQ:WW) reported its fourth-quarter and full-year 2025 results on March 16, 2026, signaling a successful stabilization of its business model following a major financial restructuring mid-year.
The company reported total revenue of $163 million for the fourth quarter, with clinical subscription revenue reaching $27 million—a significant contributor to the firm's evolving growth profile.
The standout metric for the period was the surge in clinical subscribers, which reached 130,000 at year-end, representing a 42% increase over the prior year.
This growth highlights the traction of "WeightWatchers Med+," a dedicated program that pairs GLP-1 medications with the company's signature behavioral and nutritional support.
Total end-of-period subscribers stood at 2.8 million.
While the traditional behavioral business remains under pressure, the higher average revenue per user (ARPU) from clinical members helped the company exceed its narrowed 2025 revenue and adjusted EBITDA guidance.
For the fourth quarter, WeightWatchers recorded a net loss of $6 million, a substantial improvement from the prior-year period.
Adjusted EBITDA for the quarter was $18 million, yielding an 11.1% margin.
The company’s balance sheet also showed marked improvement, ending the year with a strengthened cash position and significantly reduced debt levels following its emergence from reorganization in June 2025.
Looking toward 2026, WeightWatchers issued full-year guidance that reflects a transition toward sustainable, long-term profitability.
The company expects total revenue to land between $620 million and $635 million, with adjusted EBITDA projected in the range of $105 million to $115 million.